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Abstract
Background: The large sample sizes, freedom of ethical restrictions and ease of
repeated measurements make cytotoxicity assays of immortalized lymphoblastoid cell
lines a powerful new in vitromethod in pharmacogenomics research. However,
previous studies may have over-simplified the complex differences in dose-response
profiles between genotypes, resulting in a loss of power.
Methods: The current study investigates four previously studied methods, plus one
new method based on a multivariate analysis of variance (MANOVA) design. A
simulation study was performed using differences in cancer drug response between
genotypes for biologically meaningful loci. These loci also showed significance in
separate genome-wide association studies. This manuscript builds upon a previous
study, where differences in dose-response curves between genotypes were
constructed using the hill slope equation.
Conclusion: Overall, MANOVA was found to be the most powerful method for
detecting real signals, and was also the most robust method for detection using
alternatives generated with the previous simulation study. This method is also
attractive because test statistics follow their expected distributions under the null
hypothesis for both simulated and real data. The success of this method inspired the
creation of the software program MAGWAS. MAGWAS is a computationally efficient,
user-friendly, open source software tool that works on most platforms and performs
GWASs for individuals having multivariate responses using standard file formats.
Keywords: Pharmacogenomics, Lymphoblastoid cell lines, Chemosensitivity,
Chemotherapy, Temozolomide, Idarubicin, MANOVA, GWAS, Simulation study
Background
While genotyping technology can provide valuable individual genetic data, pharmacoge-
nomics research hasmet little success in using this data to improve patient outcomes. This
result is less surprising, considering that pharmacogenomics studies with human popu-
lations often map a limited a priori set of targeted genes for therapeutic agents whose
heritability is unknown using clinical trial data with limited sample sizes andmany poten-
tial confounders [1,2]. Developed in response to these limitations, a new in vitro assay
system utilizing dose-response (DR) profiles of immortalized lymphoblastoid cell lines
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(LCLs) allows for rapid experimental testing of multiple agents using virtually unlim-
ited sample sizes, for either linkage or association at the genome-wide level [3-13]. A
more thorough discussion of the practical benefits for using LCLs in pharmacogenomics
research can be found in recent review articles [1,2].
However, obstacles for using LCLs to identify clinically relevant loci include elucidation
of the translational relevance between donor and LCL, and the development of methods
that are powerful for using DR data in gene mapping. For this second item, gene map-
ping studies (such as in genome-wide association studies, or GWASs) attempt to find loci
with genotypes having significantly different phenotypes. For cell models and other DR
data, phenotypes are complex, and “different” is not well defined. Previous simulation
studies show that the most powerful method depends on what these differences are [14].
For example, if differences in the DR curves between genotypes are due entirely to half
inhibitory concentration (IC50), then summarizing each curve with it’s estimated IC50
and treating that as the response is the best course of action. However, if the true differ-
ences between genotypes is not IC50, then this method may not perform optimally. We
would like a method that is robust to differences in the dose-response profiles between
genotypes. We would also like a method that is very powerful at detecting those kinds of
differences that are likely to arise from biology. For instance, if a certain polymorphism
affects the expression of an enzyme involved with inactivating a drug target, what kinds of
differences in the DR profiles for LCL cytotoxicity will this polymorphism produce?Many
previous studies have fit a non-linear equation (often without testing the appropriateness
of this model) to each DR curve, choosing one parameter from this fit, and perform asso-
ciation using this parameter estimate [3-13]. As mentioned above, the “true” differences
in the DR profiles between phenotypes may not be captured by this parameter.
A previous study investigated using many different univariate summaries (such as
parameter estimates from a hill slope fit) as the response in simulated association testing
[14]. This study investigated the power each summary measure had in association testing,
using many different simulated differences in the DR profiles between genotypes. Every
summary measure performed poorly under at least one alternative. However, methods
that modeled all of the responses jointly performed at least adequately (and sometimes
very well) under every alternative. At question, however, is which alternative(s) is(are)
most representative of the differences between in the DR profiles between genotypes for
meaningful loci that are likely to be encountered in practice? To this end, the current
study uses actual differences in curves between genotypes from real data for effects that
have strong support for representing true biology. These differences will be referred to as
signals throughout. Each of these signals was created from markers that were found to be
significant in genetic association studies and also had been validated from other data or
from previous results. In this way, using real data to guide a simulation study, where these
differences can be modeled after genuine biological signals, may give a more accurate
assessment of which method performs best in practice.
Methods
Biological motivation for simulation study
The signals used for study were all from a set of GWASs of 515 LCLs exposed to
either the cancer drug temozolomide or 5-fluorouracil. A strong association (p= 3.3 ∗
10−16) was found between LCL cytotoxicity to temozolomide and locus rs531572,
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located within the gene coding for O6-methylguanine-DNA methyltransferase [MGMT :
ENSG00000170430]. In addition, a strong association (p= 6.8∗10−26) was found between
the same loci and expression levels forMGMT transcripts [15].MGMT is known to repair
DNA damaged by temozolomide, and genetic variants affecting MGMT are known to
be associated with temozolomide clinical efficacy [16]. Similarly, suggestive associations
(p = 5.9 ∗ 10−7 and ) were found between LCL cytotoxicity to 5-fluorouracil and locus
rs2270311, located within the gene coding for chimerin 2 [CHN2: ENSG00000106069].
Significant differences in the expression of CHN2 have been found between between
colon cancer cells having different levels of 5-fluorouracil resistance [17].
Figure 1 illustrates the differences in mean viabilities between genotypes at each con-
centration for temozolomide and 5-fluorouracil. The mean viability was corrected for
potentially confounding covariates by least squares regression and estimation at the sam-
ple means for each covariate. These covariates include cellular growth rate, laboratory
temperature, the first two genetic principal components and laboratory date (nominal).
Signals are due to single nucleotide polymorphisms (SNPs), where black, red and blue
circles represent genotypes for 0, 1 and 2 minor alleles, respectively.
After performing regression using the covariates mentioned above, error terms were
assessed for multivariate normality. Although the error terms failed the Shapiro-Wilk
test for multivariate normality (p= 2.8 ∗ 10−4 for temozolomide and p= 1.4 ∗ 10−8 for
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Figure 1 Real signal based on temozolomide and 5-fluorouracil response. Differences in response
between genotypes for A temozolomide at rs531572 and B 5-fluorouracil at rs2270311. Black, red and blue
dots indicate the genotypes for 0, 1 and 2 copies of the minor allele.
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5-fluorouracil, [18]), the goal of this simulation was to use real data as a guide in simu-
lation. To this end, residuals were first transformed to be standardized and uncorrelated,
according to [19]. Then histograms of errors for each drug concentration were overlaid
with standard normal densities in Figures 2 and 3. In addition, Figures 4 and 5 show scat-
ter plots of residuals between each pair of drug concentrations for temozolomide and
5-fluorouracil. Although the distribution of errors are definitely not normal, from these
plots it appears, at least visually, that the deviations from normality (with the exception
of a few outliers) are not severe.
Simulation and power comparisons of cell line methods
A simulation study was performed using the appropriate estimated means and error
covariances, as described in the previous section. Using parameter estimates from these
biological signals, data were generated as multivariate normal according to:
Yijk ∼ N6(μ˜i, ̂)
μ˜i = μ̂0 + ES
[
β̂1I(i = 1) + β̂2I(i = 2)
]
β̂m = μ̂m − μ̂0, m ∈ 1, 2
(1)
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Figure 2 Histograms for temozolomide at rs531572. Histogram of residuals for temozolomide at rs531572,
with standard normal densities overlaid. Panels A - F are for transformed residuals for highest to lowest drug
concentrations.
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Figure 3 Histograms for 5-fluorouracil at rs2270311. Histogram of residuals for 5-fluorouracil at rs2270311,
with standard normal densities overlaid. Panels A - F are for transformed residuals for highest to lowest drug
concentrations.
where Yijk is the vector of viabilities for six concentrations for the kth replication of the jth
individual having genotype i (the number of minor alleles). Here, ̂ is the sample covari-
ance of errors, μ̂i is the vector of mean viabilities for genotype i, and ES is the effect size.
Effect sizes ranged from 0 (corresponding to the null) to 1.0 (the observed differences
between genotypes). The sample size was set to 500 and minor allele frequency (MAF)
was set to 0.5.
For each effect size and signal, 2500 data sets were used to calculate test statis-
tics for four previously reported methods (IC50, Slope, AUCEmp and ANOVA) [14],
as well as a new method using Pillai’s trace from a multivariate analysis of vari-
ance (MANOVA) [20]. In addition, 10,000 data sets were created with an effect
size of zero, and a different random number seed, to represent the null distribu-
tion. In this way, p-values for each test statistic under the alternative distribution
were estimated by the proportion of larger statistics under the null distribution,
as described in [14]. This was required, for the ANOVA method, as applied to
all (non-independent) observations, generated test statistics that did not follow the
expected distribution under the null. Power curves describing the proportion of
times the null hypothesis of no difference between genotypes was rejected, at the
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Figure 4 Scatter plots for temozolomide at rs531572. Scatter plots of residual vectors between each pair
of drug concentrations for temozolomide. Plots A - O represent residuals between drug concentrations 1
and 2, 1 and 3, . . ., 5 and 6.
alpha = 0.05 level, are illustrated in Figure 6, where panels A and B represent
the power curves for simulation using signals from temozolomide/MGMT and
5-fluorouracil/CHN2.
In addition, each of these same methods were compared using a previous simula-
tion described in [14], where differences in the DR curves between genotypes are due
to differences in the distribution of hill slope parameters. Figure 6 gives power curves
for a representative sample of these simulations, where data were simulated under an
additive genetic model, with equally spaced drug dosages and a MAF of 0.5. Panels
C - E represent power curves for each method where differences in curves between
genotypes are due to the “Min”, “IC50” and “Slope” parameter distributions, respectively.
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Figure 5 Scatter plots for 5-fluorouracil at rs2270311. Scatter plots of residual vectors between each pair
of drug concentrations for 5-fluorouracil. Plots A - O represent residuals between drug concentrations 1 and
2, 1 and 3, . . ., 5 and 6.
Using the Friedman test, significant differences (p < 10−15 for all) in p-values were
found between methods for every positive (i.e. non-null) effect size for both sets of
simulations.
Also, the effect of modifying the error structures from Equation 1 were explored.
Here, the mean vectors μi across genotypes i were taken from the signal for temozolo-
mide/MGMT but the covariance matrix  was modified to represent various contrived
correlation structures. This was done to assess how sensitive the power of MANOVA
was to error structures and also to the assumption of multivariate normality. The cho-
sen error structures include equal correlations using compound symmetric (i.e. constant)
correlation (with ρ = 0.25, 0.5 or 0.75), autoregressive (exponential attenuation) corre-
lation (with ρ = 0.25, 0.5 or 0.75) and no correlation. In addition, errors were generated
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Figure 6 Power curves for real and contrived alternatives. Panels A and B are real signals based on LCL
response to temozolomide at rs531572 (within the gene MGMT) and 5-fluorouracil at rs2270311 (located
within the gene CHN2), respectively. Panels C, D and E are for differences between genotypes being due to
the hill slope parameters, “Min”, “IC50” and “Slope” from [14].
independently, but using a centered gamma distribution with parameters shape=8 and
scale=0.125. The results for each of these simulations is shown in Figure 7.
Finally, simulations were performed to assess the strength of MANOVA with data gen-
erated using multivariate normal, but under non-ideal situations. For these, mean vectors
and covariances were constructed from 12 equally-spaced doses. The difference in mean
vectors between genotypes were designed to follow a specific univariate summary, includ-
ing area under the curve, and the hill slope parameters “Min”, “IC50” and “Slope”, as
illustrated in Figure 8. Using these mean vectors, simulations were performed where error
terms follow an exponential decay correlation structure, with ρ = 0.25. Power plots from
these simulations are illustrated in Figure 9.
Results and discussion
The simulated data (for the current study) were generated using a multivariate normal
model. In addition, MANOVA has an assumption of multivariate normality. This appears
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Figure 7 Power curves for various error structures. Power plots using the signal from
temozolomide/MGMT with different error structures are shown in all panels. Panels A, C and E are under
equal correlation with ρ = 0.75, 0.5 and 0.25, respectively. Panels B, D and F are under exponential
correlation with ρ = 0.75, 0.5 and 0.25, respectively. Panels G and H had error terms generated
independently as normal and gamma, respectively.
as an intentional way to provide MANOVA with an advantage, since correct modeling
assumptions are guaranteed. However, our goal was actually to identify a statistical model
with sufficient complexity to accurately capture most aspects of the real data. In addition,
the univariate summary methods rely on ANOVA, a statistical method that is robust to
the assumption of normality, reducing the inherent advantage MANOVA has over the
other methods. Indeed, even though data generation was under multivariate normality,
MANOVA is not assured to be the most powerful for every situation. First, if the number
of responses is large, power attenuates, since the number of covariance parameters need-
ing to be estimated grows with the square of the number of responses. Second the power
of MANOVA compared to other methods seems to be reduced when the off-diagonal
covariance parameters decreases. This is shown in Figure 7, where the mean vectors
for each genotype are modeled after the temozolomide and MGMT signal, but residual
covariances are modeled using an exponential decay or equal correlation. Here, the domi-
nating power of MANOVA over the other methods is reduced as the correlation between
residuals decreases. A final way in which MANOVA may not perform optimally, com-
pared with other methods, is when the differences in the DR profiles between genotypes
Brown et al. BioDataMining 2012, 5:21 Page 10 of 15
http://www.biodatamining.org/content/5/1/21
0.02 0.06 0.10
0.
2
0.
4
0.
6
0.
8
1.
0A
Concentration
Vi
ab
ilit
y
0.02 0.06 0.10
0.
2
0.
4
0.
6
0.
8
1.
0B
Concentration
Vi
ab
ilit
y
0.02 0.06 0.10
0.
2
0.
4
0.
6
0.
8
1.
0C
Concentration
Vi
ab
ilit
y
0.02 0.06 0.10
0.
2
0.
4
0.
6
0.
8
1.
0D
Concentration
Vi
ab
ilit
y
Figure 8 Dose response curves for used for non-ideal conditions. Dose response curves used for
generating data that are not ideal for MANOVA, where differences between genotypes are designed to
follow univariate summary statistics. Panel A represents area under the curve and panels B - D are for the hill
slope parameters “Min”, “IC50” and “Slope”, respectively.
are due entirely to a simple summary measure. These ideas are illustrated in Figures 8 and
9, where data are generated for large (12) vector responses, correlations are low (ρ = 0.25)
and differences in the DR curves between genotypes can be summarized well using sim-
ple summary measures. In this case, the MANOVA method does not perform optimally,
even though data are generated using a multivariate normal model.
It is also interesting to observe how well MANOVA performs when the assumption
of multivariate normality is violated. The previous simulation study relied on generat-
ing random hill slope lines, and adding error terms that follow a Laplace distribution.
Even though the resulting response vectors deviate far from normal (results not shown),
MANOVA still performs surprisingly well. Although never the most powerful method
under these conditions, MANOVA was consistently among the most powerful, and had
best performance across a range of hill slope alternatives. A few of these are illustrated
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Figure 9 Power curves for non-ideal conditions. Shown are power curves for data generated using the DR
curves from Figure 8, using an exponential decay correlation structure with ρ = 0.25. Panels A - D are for
area under the curve, “Min”, “IC50” and “Slope” parameters, respectively.
in Figure 6. In addition, the advantage of MANOVA is actually increased over the other
methods for the temozolomide/MGMT signal when the distribution of the error terms
change from multivariate normal to gamma. These results need to be cautioned, how-
ever, because all p-values were generated using resampling techniques, described in [14].
When compared to their expected distributions, MANOVA test statistics generated from
the hill slope-type simulations are well-behaved, but the same test statistics generated
with gamma distributed error terms behave quite poorly (Figure 10). This latter case
would lead to inflated type-I error rates, if p-values are calculated using the expected null
asymptotic distribution.
Software implementing MANOVA in GWASs: Introducing MAGWAS
Because of the power and robustness of the MANOVA design in detecting true biological
signals in LCL response, andmore generally the need for analysis tools for GWASs having
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Figure 10 MANOVA test statistic QQ plots. Shown are QQ plots of MANOVA test statistics generated under
the null, based on temozolomide/MGMT (panel A), 5-fluorouracil/CHN2 (panel B), random hill slope curves
from a previously reported simulation (panel C) [14], and error structures following a gamma distribution
(panel D).
multivariate responses, the programMAGWAS (multivariate ANOVA genome-wide asso-
ciation software) was developed [21]. MAGWAS calculates the significance of each single
nucleotide polymorphisms (SNP), allows for inclusion of confounding variables and uses
PLINK file formats [22,23]. The program is free, fast to download (less than 1 MB),
requires no installation, is platform independent and runs using a single line on a system’s
command prompt. In addition, MAGWAS is efficient with system memory and GWASs
are generally completed in much less than an hour on typical desktop systems. Indeed,
analysis of the two data sets for the present study where each data set had about 500 indi-
viduals, and each individual having six responses and 33 covariates, repeated across about
2 million SNPs took less than 17 minutes apiece on a modest computing cluster (two
Intel(R) Xeon(R) CPU E5450 processors). MAGWAS is written completely in Java and is
registered as open source software under a GNU public license. Matrix manipulations are
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accomplished using the Java package JAMA [24] and distributional calculations are made
using the Java package DistLib [25].
Conclusions
In conclusion, no method is uniformly superior for modeling the genetic effects for DR
cell line data. However, unlike other univariate summary methods (such as estimating the
IC50 for each DR curve and treating this estimate as the response), MANOVA makes
no assumption about the nature of the DR curve or about what the differences in the
DR curves between genotypes are expected to be. Unsurprisingly, using simulated data
from a previous study, MANOVA was the only method that had good power under all
alternatives considered. In addition, MANOVA was most powerful in detecting differ-
ences between genotypes for simulations based on signals obtained from real data. A final
advantage of using MANOVA is that test statistics asymptotically follow a known distri-
bution under the null, allowing for fast and accurate analysis of each loci in a GWAS, so
long as sample sizes are not small. Quantile-quantile (QQ) plots of the null distributions
of test statistics from this study, as well as the null for the previous simulation, demon-
strate that the type I error rate is under control in all conditions, except when data are
generated using a gamma distribution for the error structure. Figure 10 shows four repre-
sentative examples of these QQ plots. Under the assumption that most loci have no true
association in genome-wide data, a similar result was found for QQ plots from a sepa-
rate set of GWASs (results not shown) involving LCL response to 29 different anticancer
drugs.
On the other hand, MANOVA is not guaranteed to always be optimal, especially if the
number of responses for each individual is large, the correlations between responses are
small, and/or the true differences in DR curves between genotypes are known to be due
to entirely to single univariate summary measure. Also, the interpretation for MANOVA
is somewhat more complicated, as traditional measures of effect size, such as model r-
squared (R2) and parameter estimates are not immediately clear. For example, R2 may
vary substantially between responses at each concentration. Similarly, parameter esti-
mates for the effect of SNP are unlikely to be the same, and may even have opposite
directions, at different concentrations. Overall, we feel the benefits outweigh the handi-
caps and that MANOVA is a great method for gene mapping, or other association tests
utilizing DR data.
The current study explored two basic classes of linear models as methods for testing
differences between genotypes for DR data. These include using ANOVA to model the
differences in DR summary measures, and using MANOVA to model the differences
between response vectors jointly. However, several other methods could potentially be
applied for modeling DR data. One of these includes adapting methods from longitudi-
nal and repeated measures data analysis [26]. If the basic form of the covariance structure
between residuals were known, these methods could potentially reduce the number of
parameters being estimated, and may be ideal, especially in situations where the number
of responses (concentrations) for each individual is rather large. Another set of methods
employ semi and non-parametric designs for mapping quantitative trait loci [27-29]. Semi
(non)-parametric designs are attractive because they use minimal (no) modeling assump-
tions, therefore guarding against incorrect model specification. Future studies would
benefit from comparing these designs to MANOVA in DR data from LCL cytotoxicities.
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